Integrating Oral SERDs: HR+/HER2- BC
Integrating Oral SERDs Into Treatment for Patients With HR-positive/HER2-negative Metastatic Breast Cancer and Current Rationale or Medical Need

Released: November 13, 2024

Expiration: November 12, 2025

Activity

Progress
1
Course Completed